IL32 and prostate adenocarcinoma: Differential expression of IL32 was significant among N stages for PRAD (p = 9.1e-4), THCA (p = 8.1e-3), PAAD (p = 0.03) and SKCM (p = 0.03), as well as for M stages of KIRC (p = 1.5e-4) (Fig. 2B).